Our Services

Early-stage, private, or public companies seeking partners or non-dilutive capital.

- Conduct in-depth due diligence and market research analyses for assets of interest.
- Develop detailed forecasts and valuation models to quantify asset value.
- Design tailored transaction structures that optimize risk and reward.
- Map the investor landscape and manage end-to-end monetization processes.
- Identify and prioritize potential licensing or co-development partners.
- Develop data-room materials, pitch decks, and valuation frameworks.
- Support outreach, diligence, and negotiations through term-sheet execution.
- Build detailed commercial forecasts for products integrating patient-level epidemiology, launch curves, product pricing
- Design payment waterfall and milestone scenarios to inform deal strategy and buyer discussions.
- Evaluate non-dilutive and hybrid financing options (royalty, debt, structured equity).
- Advise on sequencing of capital events relative to clinical and regulatory catalysts.
- Develop investor-ready materials including valuation models, memos, and FAQs.
- Stress-test key assumptions ahead of partnering or fundraising initiatives.

Early-stage, private, or public companies seeking partners or non-dilutive capital.

- Position early-stage IP for pharma/biotech partnering.
- Benchmark comparable deals and identify target partners.
- Create non-confidential summaries and value ranges for negotiation.
- Evaluate and advise on royalty and milestone frameworks in licensing negotiations.
- Model potential deal economics across alternative structures.
- Assess whether to license out or spin out IP into a new company.
- Build early-stage business plans and capital needs models.

Royalty buyers, crossover investors, or credit funds.

- Conduct commercial, clinical, and contractual diligence on potential royalty or structured credit assets.
- Build detailed cash-flow and scenario models to support internal underwriting.
- Assess embedded royalty or milestone exposure within existing portfolios.
- Identify under-leveraged assets suitable for secondary monetization.
- Identify, profile, and evaluate new royalty and non-dilutive financing opportunities.
- Support preparation of internal IC materials and sensitivity analyses.

Disease-specific organizations or foundations with IP or funding exposure.

- Determine the value and timing of royalty and milestone entitlements.
- Build models and materials to support board decision-making or process launches.
- Design co-funding or risk-sharing arrangements with industry partners.
- Negotiate terms that balance mission impact with financial sustainability.